Stock Events

Stock Events

NervGen Pharma 

$1.7500
55
+$0.01+0.57%Thursday 20:00
+$0.00+0%Thursday 23:30After hours

Statistics

Day High
1.765
Day Low
1.73
52W High
6.3
52W Low
1.58
Volume
26,066
Avg. Volume
-
Mkt Cap
188.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.23
-0.16
-0.09
-0.01
Expected EPS
-0.08414138169
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-32.03MNet Income

Analyst Ratings

$15.00Average Price Target
The highest estimate is ⁦15.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NGEN. It's not an investment recommendation.
NVIDIA
7
NVDA
Amazon
5
AMZN
Enbridge
5
ENB.TO
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurodegenerative diseases, directly competing with NervGen's focus on nerve damage and repair.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly has a strong pipeline in Alzheimer's and other neurological conditions, overlapping with NervGen's therapeutic areas.
Novavax
NVAX
Mkt Cap1.73B
Novavax, while primarily known for vaccines, is expanding into treatments for neurological disorders, potentially competing with NervGen.
Pfizer
PFE
Mkt Cap158.45B
Pfizer has a broad interest in neurological diseases, including Alzheimer's, which could compete with NervGen's research and development.
Merck
MRK
Mkt Cap356.01B
Merck is involved in neurology and has been expanding its research in neurodegenerative diseases, making it a competitor.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie has a growing interest in neuroscience, including R&D in Alzheimer's and Parkinson's, areas of interest for NervGen.
AMGEN
AMGN
Mkt Cap217.9B
Amgen has a focus on neuroscience and is developing treatments for Alzheimer's and other brain disorders, competing with NervGen.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca has a diverse neurology portfolio, including treatments for neurological disorders that overlap with NervGen's focus.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, though known for antivirals, is expanding into oncology and inflammatory diseases, including neurological conditions that may compete with NervGen.

About

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Show More
CEO
Adam H. Rogers
Employees
9
Country
Canada
ISIN
CA64082X2032
WKN
000A2QP3D

Listings

STU
DE
9UA.STU
MU
DE
9UA.MU
V
CA
NGEN.V
F
DE
9UA.F

0 Comments

Share your thoughts

FAQs

What is NervGen Pharma stock price today?▼
The current price of NGEN is $1.75 USD — it has increased by +0.57% in the past 24 hours. Watch NervGen Pharma stock price performance more closely on the chart.
What is NervGen Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NervGen Pharma stocks are traded under the ticker NGEN.
What is NervGen Pharma market cap?▼
Today NervGen Pharma has the market capitalization of 188.16M
When is the next NervGen Pharma earnings date?▼
NervGen Pharma is going to release the next earnings report on November 12, 2026.
What were NervGen Pharma earnings last quarter?▼
NGEN earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.06 USD resulting in a -338.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NervGen Pharma revenue for the last year?▼
NervGen Pharma revenue for the last year amounts to 0 USD.
What is NervGen Pharma net income for the last year?▼
NGEN net income for the last year is -32.03M USD.
How many employees does NervGen Pharma have?▼
As of October 9, 2026, the company has 9 employees.
In which sector is NervGen Pharma located?▼
NervGen Pharma operates in the Health & Wellness sector.
When did NervGen Pharma complete a stock split?▼
NervGen Pharma has not had any recent stock splits.
Where is NervGen Pharma headquartered?▼
NervGen Pharma is headquartered in West Vancouver, Canada.